-
Endo Pharmaceuticals Inc. v. Actavis Inc. et al DC CAFC
- 1:12-cv-08985
- S.D.N.Y.
- Judge: J. Paul Oetken
+1
- Filed: 12/11/2012
- Closed: 06/29/2016
- Latest Docket Entry: 11/09/2023
- PACER
1
Plaintiff
2
Defendants
2
Accused
Products
3
Patents-in-Suit
1,297
Days in
Litigation
-
Endo Pharmaceuticals Inc. v. Actavis Inc. et al DC CAFC
- 1:12-cv-08985
- S.D.N.Y.
- Judge: J. Paul Oetken
+1
- Filed: 12/11/2012
- Closed: 06/29/2016
- Latest Docket Entry: 11/09/2023
- PACER
Market Sector
Biotech and Pharma
Referred Judge
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
-
Infringement
Actavis Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Opana ER CRFGeneric Oxymorphone ER | US 7,851,482 B2 | All Asserted Claims |
No infringement
Entry 73
|
| Generic Opana ER CRFGeneric Oxymorphone ERgeneric version of OPANA ER | US 8,309,122 B2 | All Asserted Claims |
Infringement
Entry 171Entry 108 Entry 96 |
| Generic Opana ER CRFGeneric Oxymorphone ERgeneric version of OPANA ER | US 8,329,216 B2 | All Asserted Claims |
Infringement
Entry 108Entry 96 |
Actavis South Atlantic LLC
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic Opana ER CRFGeneric Oxymorphone ER | US 7,851,482 B2 | All Asserted Claims |
No infringement
Entry 73
|
| Generic Opana ER CRFGeneric Oxymorphone ERgeneric version of OPANA ER | US 8,309,122 B2 | All Asserted Claims |
Infringement
Entry 171Entry 108 Entry 96 |
| Generic Opana ER CRFGeneric Oxymorphone ERgeneric version of OPANA ER | US 8,329,216 B2 | All Asserted Claims |
Infringement
Entry 108Entry 96 |
